HUP0103781A3 - Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition - Google Patents

Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition

Info

Publication number: HUP0103781A3
Authority: HU; Hungary
Prior art keywords: antiphsychotic; atypical; agent; combination; pharmaceutical compositions
Prior art date: 1998-10-16

Application number

HU0103781A

Other languages

Hungarian (hu)

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-16

Filing date

1999-10-12

Publication date

2003-09-29

1999-10-12 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2002-03-28 Publication of HUP0103781A2 publication Critical patent/HUP0103781A2/en

2003-09-29 Publication of HUP0103781A3 publication Critical patent/HUP0103781A3/en

Links

229940100578 Acetylcholinesterase inhibitor Drugs 0.000 title 1
239000003795 chemical substances by application Substances 0.000 title 1
239000000544 cholinesterase inhibitor Substances 0.000 title 1
230000019771 cognition Effects 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

HU0103781A 1998-10-16 1999-10-12 Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition HUP0103781A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP98203454		1998-10-16
PCT/EP1999/007804 WO2000023057A2 (en)	1998-10-16	1999-10-12	Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition

Publications (2)

Publication Number	Publication Date
HUP0103781A2 HUP0103781A2 (en)	2002-03-28
HUP0103781A3 true HUP0103781A3 (en)	2003-09-29

Family

ID=8234219

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU0103781A HUP0103781A3 (en)	1998-10-16	1999-10-12	Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition

Country Status (20)

Country	Link
EP (1)	EP1121131A2 (en)
JP (1)	JP2002527469A (en)
KR (1)	KR20010072878A (en)
CN (1)	CN1367697A (en)
AU (1)	AU6472799A (en)
BG (1)	BG105302A (en)
BR (1)	BR9914419A (en)
CA (1)	CA2345767A1 (en)
EE (1)	EE200100136A (en)
HK (1)	HK1039745A1 (en)
HR (1)	HRP20010262A2 (en)
HU (1)	HUP0103781A3 (en)
ID (1)	ID28441A (en)
IL (1)	IL142588A0 (en)
NO (1)	NO20011403L (en)
PL (1)	PL348107A1 (en)
SK (1)	SK4592001A3 (en)
TR (1)	TR200101082T2 (en)
WO (1)	WO2000023057A2 (en)
ZA (1)	ZA200103081B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2006201188B2 (en) *	2001-02-05	2007-11-15	Novartis Ag	New use of iloperidone
GB0102841D0 (en) *	2001-02-05	2001-03-21	Novartis Ag	Organic compounds
EP2295058B1 (en) *	2001-10-30	2013-09-04	Novartis AG	Depot formulations of iloperidone with a polymer
GB0216416D0 (en)	2002-07-15	2002-08-21	Novartis Ag	Organic compounds
WO2004084905A2 (en) *	2003-03-24	2004-10-07	University Of Florida	Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions
TW200501962A (en) *	2003-04-01	2005-01-16	Novartis Ag	Use of carbamazepine derivatives for the treatment of agitation in dementia patients
CA2552221A1 (en) *	2003-12-31	2005-07-21	Actavis Group Hf	Donepezil formulations
AU2004325725A1 (en) *	2004-12-10	2006-06-22	Abbott Laboratories	Fused bicycloheterocycle substituted quinuclidine derivatives
WO2008055945A1 (en)	2006-11-09	2008-05-15	Probiodrug Ag	3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en)	2006-11-30	2015-09-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase
CN101668525A (en)	2007-03-01	2010-03-10	前体生物药物股份公司	New use of glutaminyl cyclase inhibitors
EP2865670B1 (en)	2007-04-18	2017-01-11	Probiodrug AG	Thiourea derivatives as glutaminyl cyclase inhibitors
MX2007008642A (en) *	2007-07-16	2009-02-25	World Trade Imp Export Wtie Ag	Pharmaceutical composition comprising the combination of a benzisoxazolic derived agent and a reversible inhibiting agent of the cholinesterase enzyme prescribed for the control and treatment of psychotic disorders and dementias.
JP6082250B2 (en)	2010-02-09	2017-02-15	ザ・ジョンズ・ホプキンス・ユニバーシティー	Methods and compositions for improving cognitive function
US9181233B2 (en)	2010-03-03	2015-11-10	Probiodrug Ag	Inhibitors of glutaminyl cyclase
AU2011226074B2 (en)	2010-03-10	2015-01-22	Vivoryon Therapeutics N.V.	Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
WO2011131748A2 (en)	2010-04-21	2011-10-27	Probiodrug Ag	Novel inhibitors
DK2686313T3 (en)	2011-03-16	2016-05-02	Probiodrug Ag	Benzimidazole derivatives as inhibitors of glutaminyl cyclase
WO2014078568A1 (en)	2012-11-14	2014-05-22	The Johns Hopkins University	Methods and compositions for treating schizophrenia
WO2014144663A1 (en)	2013-03-15	2014-09-18	The Johns Hopkins University	Methods and compositions for improving cognitive function
EP2968220B1 (en)	2013-03-15	2021-05-05	Agenebio, Inc.	Methods and compositions for improving cognitive function
CA2986598C (en)	2015-05-22	2023-09-26	Agenebio, Inc.	Extended release pharmaceutical compositions of levetiracetam
DK3461819T3 (en)	2017-09-29	2020-08-10	Probiodrug Ag	GLUTAMINYL CYCLASE INHIBITORS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0515301A3 (en) *	1991-05-14	1993-06-16	Ernir Snorrason	Improvements in benzodiazepine treatment by cholinesterterase inhibitors
US5336675A (en) *	1991-05-14	1994-08-09	Ernir Snorrason	Method of treating mania in humans
CA2300148C (en) *	1997-08-11	2009-06-23	University Of South Florida	Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
EP1844769A3 (en) *	1998-04-14	2010-02-10	The General Hospital Corporation	Methods for treating neuropsychiatric disorders

1999
- 1999-10-12 KR KR1020017002286A patent/KR20010072878A/en not_active Application Discontinuation
- 1999-10-12 PL PL99348107A patent/PL348107A1/en unknown
- 1999-10-12 WO PCT/EP1999/007804 patent/WO2000023057A2/en not_active Application Discontinuation
- 1999-10-12 CN CN99812184A patent/CN1367697A/en active Pending
- 1999-10-12 AU AU64727/99A patent/AU6472799A/en not_active Abandoned
- 1999-10-12 BR BR9914419-0A patent/BR9914419A/en not_active IP Right Cessation
- 1999-10-12 ID IDW20010828A patent/ID28441A/en unknown
- 1999-10-12 TR TR2001/01082T patent/TR200101082T2/en unknown
- 1999-10-12 JP JP2000576832A patent/JP2002527469A/en not_active Withdrawn
- 1999-10-12 SK SK459-2001A patent/SK4592001A3/en unknown
- 1999-10-12 IL IL14258899A patent/IL142588A0/en unknown
- 1999-10-12 CA CA002345767A patent/CA2345767A1/en not_active Abandoned
- 1999-10-12 HU HU0103781A patent/HUP0103781A3/en unknown
- 1999-10-12 EP EP99952580A patent/EP1121131A2/en not_active Withdrawn
- 1999-10-12 EE EEP200100136A patent/EE200100136A/en unknown
2001
- 2001-03-01 BG BG105302A patent/BG105302A/en unknown
- 2001-03-20 NO NO20011403A patent/NO20011403L/en not_active Application Discontinuation
- 2001-04-10 HR HR20010262A patent/HRP20010262A2/en not_active Application Discontinuation
- 2001-04-12 ZA ZA200103081A patent/ZA200103081B/en unknown
2002
- 2002-01-10 HK HK02100158.6A patent/HK1039745A1/en unknown

Also Published As

Publication number	Publication date
AU6472799A (en)	2000-05-08
HUP0103781A2 (en)	2002-03-28
CN1367697A (en)	2002-09-04
PL348107A1 (en)	2002-05-06
SK4592001A3 (en)	2001-12-03
EE200100136A (en)	2002-06-17
TR200101082T2 (en)	2001-09-21
NO20011403D0 (en)	2001-03-20
HRP20010262A2 (en)	2002-06-30
NO20011403L (en)	2001-03-20
EP1121131A2 (en)	2001-08-08
ID28441A (en)	2001-05-24
CA2345767A1 (en)	2000-04-27
ZA200103081B (en)	2002-07-12
IL142588A0 (en)	2002-03-10
HK1039745A1 (en)	2002-05-10
JP2002527469A (en)	2002-08-27
KR20010072878A (en)	2001-07-31
WO2000023057A3 (en)	2000-07-27
WO2000023057A2 (en)	2000-04-27
BR9914419A (en)	2001-06-26
BG105302A (en)	2001-11-30

Similar Documents

Publication	Publication Date	Title
HUP0103781A3 (en)	2003-09-29	Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition
IL206621A0 (en)	2010-12-30	Caspase inhibitors and pharmaceutical compositions containing the same
HUP0104768A3 (en)	2002-05-28	4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same
HUP0302922A3 (en)	2007-02-28	Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation and pharmaceutical compositions containing them
HUP0101810A3 (en)	2002-05-28	Substituted oxoazaheterocyclyl factor xa inhibitors and pharmaceutical compositions containing them
IL177018A0 (en)	2009-02-11	Cyclopropyl-fused pyrrolidine derivatives and pharmaceutical compositions containing the same
IL150224A0 (en)	2002-12-01	Lipopeptides and pharmaceutical compositions containing the same
IL150223A0 (en)	2002-12-01	Lipopeptides and pharmaceutical compositions containing the same
IL144977A0 (en)	2002-06-30	Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
HUP0203971A3 (en)	2005-01-28	Imidazoimidazoles and triazoles as anti-inflammatory agents and pharmaceutical compositions containing them and their use
HUP0105113A3 (en)	2004-11-29	Benzoheterocycles and their use as mek inhibitors and pharmaceutical compositions containing the compounds
IL152451A0 (en)	2003-05-29	2-chloro-2-nitrophenylcarboxamide derivatives and pharmaceutical compositions containing the same
HUP0301178A3 (en)	2009-08-28	Glucopyranosyloxybenzylbenzene derivatives and pharmaceutical compositions containing the same
IL153123A0 (en)	2003-06-24	N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same
HUP0203378A3 (en)	2004-07-28	Pharmaceutical compounds and pharmaceutical compositions containing them
IL142665A0 (en)	2002-03-10	Acyl dipeptidyl derivatives and pharmaceutical compositions containing the same
HUP0103188A2 (en)	2001-12-28	Compounds and compositions for delivering active agents
HUP0203728A3 (en)	2003-12-29	Aerosol composition comprising formoterol
IL150077A0 (en)	2002-12-01	Heterocyclic compounds and pharmaceutical compositions containing the same
IL152315A0 (en)	2003-05-29	Soluble ctla4 mutant molecules and pharmaceutical compositions containing the same
IL152718A0 (en)	2003-06-24	Piperidine derivatives and pharmaceutical compositions containing the same
HUP0103256A3 (en)	2002-05-28	Thiobenzimidazole derivatives and pharmaceutical compositions containing the compounds
IL143920A0 (en)	2002-04-21	3-heteroarylidenyl-2-indolinone derivatives and pharmaceutical compositions containing the same
IL123143A (en)	2001-08-26	Pharmaceutical compositions containing mupirocin
IL147214A0 (en)	2002-08-14	1-methylcarbapenem derivatives and pharmaceutical compositions containing the same